KNG1 and hereditary angioedema: To interfere with polyP/FXIIa-driven inflammation plasma derived C1INH (BerinertTM) and B2R antagonist (IcatibantTM) dampen bradykinin formation and signaling and have been used for treatment of excessive bradykinin-mediated swellings in HAE patients (121, 122).